Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients

Amira Mohamed Taha; Ahmed Saad Elsaeidy; Sarah A Nada; Sadish Sharma; Mohamed M Ghonaim; Areeba Ahsan; Marina Ramzy Mourid; Khaled Abouelmagd

doi:10.1007/s40261-024-01401-y

Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients

Clin Drug Investig. 2024 Nov 11. doi: 10.1007/s40261-024-01401-y. Online ahead of print.

Authors

Amira Mohamed Taha¹, Ahmed Saad Elsaeidy², Sarah A Nada³, Sadish Sharma⁴, Mohamed M Ghonaim⁵, Areeba Ahsan⁶, Marina Ramzy Mourid⁷, Khaled Abouelmagd⁸

Affiliations

¹ Faculty of Medicine, Fayoum University, Fayoum, Egypt.
² Faculty of Medicine, Benha University, Benha, Egypt. AhmedSaadElsaeidy@gmail.com.
³ Faculty of Medicine, Menoufia University, Menoufia, Egypt.
⁴ Faculty of Medicine, College of Medical Sciences, Bharatpur, Nepal.
⁵ Faculty of Medicine, Menoufia University, Shibin Al Kawm, Egypt.
⁶ Foundation University School of Health Sciences, Islamabad, Pakistan.
⁷ Faculty of Medicine, Alexandria University, Alexandria, Egypt.
⁸ Cardiology Department, Faculty of Medicine, Al-Azhar University, New Damietta, Egypt.

PMID: 39527395
DOI: 10.1007/s40261-024-01401-y

Abstract

Background: Iron deficiency is prevalent among heart failure patients and is associated with worse clinical outcomes, including decreased quality of life and functional capacity. This condition often results in a higher incidence of hospitalization and mortality. Iron supplementation, particularly with intravenous ferric carboxymaltose (FCM), has shown potential benefits as an adjunct therapy in heart failure management. This study aims to evaluate the efficacy of FCM in the treatment of patients with heart failure and iron deficiency anemia, with a focus on its impact on mortality and hospitalization rates.

Methods: A comprehensive search was conducted in PubMed, Web of Science, and Scopus databases from their inception until 1st December 2023. Meta-analysis was performed using RevMan 5.4, employing a random-model effect. The results were reported as risk ratios (RRs), standard mean differences (SMDs), and 95 % confidence intervals (CIs).

Results: The meta-analysis included 13 studies with a total of 6271 patients. Ferric carboxymaltose administration resulted in a significant improvement in the 6-minute walk distance (SMD: 1.45; 95 % CI: 0.55, 2.36; p = 0.002), quality of life, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) (SMD: 1.49; 95 % CI: 0.87, 2.11; p < 0.00001), the rate of first hospitalization for heart failure or cardiovascular death (RR: 0.91; 95 % CI: 0.84, 0.98; p = 0.02). However, FCM did not show a significant impact on the risk of cardiovascular death (RR: 0.90; 95 % CI: 0.77, 1.05; p = 0.17), the need for intervention due to worsening heart failure (RR: 0.41; 95 % CI: 0.04, 4.51; p = 0.47), or all-cause mortality rates (RR: 0.89; 95 % CI: 0.69, 1.16; p = 0.28).

Conclusion: While FCM treatment in patients with heart failure and iron deficiency anemia significantly improves functional capacity and quality of life, it has no notable effect on mortality rates or the likelihood of hospitalization. These findings highlight the need for further research to explore comprehensive treatment strategies that address both the symptomatic and survival aspects of heart failure management in this patient population.

Publication types

Systematic Review